Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats.

Estrogens exert beneficial metabolic effects by reducing food intake and enhancing energy expenditure through both central and peripheral mechanisms. The decrease of estrogen, as occurs in ovariectomy (OVX), leads to metabolic disturbances, such as increased body weight, adipose tissue mass, basal blood glucose, and impaired glucose tolerance. These effects can be reversed by reintroducing estrogen. GLP-1 and its receptor agonists, known for their antihyperglycemic properties, also exhibit anorexigenic effects. Besides that, research indicates that GLP-1 analogs can induce metabolic changes peripherally, such as increased fatty acid oxidation and inhibited lipogenesis. Given the shared metabolic actions of GLP-1 and estrogens, we explored whether liraglutide, a GLP-1 agonist, could mitigate the metabolic effects of estrogen deficiency. We tested this hypothesis using ovariectomized rats, a model that simulates menopausal estrogen deficiency, and treated them with either liraglutide or 17ß-Estradiol benzoate for 21 days. Ovariectomy resulted in elevated DPP-IV activity in both plasma and inguinal white adipose tissue (iWAT). While estrogen replacement effectively countered the DPP-IV increase in both plasma and iWAT, liraglutide only prevented the rise in iWAT DPP-IV activity. Liraglutide prevented body weight and fat mass gain after ovariectomy to the same extent as estradiol treatment. This can be explained by the lower food intake and food efficiency caused by estradiol and liraglutide. However, liraglutide was associated with increased pro-inflammatory cytokines and inflammatory cells in white adipose tissue. Further research is crucial to fully understand the potential benefits and risks of using GLP-1 receptor agonists in the context of menopause.

Effect of Gestational Fish Oil Supplementation on Liver Metabolism and Mitochondria of Male and Female Rat Offspring Programmed by Maternal High-Fat Diet.

SCOPE: Perinatal maternal moderately high-fat diet (mHFD) is associated with obesity and fatty liver disease in offspring, and maternal fish oil (FO: n-3 PUFA source) supplementation may attenuate these disorders. This study evaluates the effects of FO given to pregnant rats fed a mHFD on the offspring's liver at weaning. METHODS AND RESULTS: Female Wistar rats receive an isoenergetic, control (CT: 10.9% from fat) or high-fat (HF: 28.7% from fat) diet before mating, and throughout pregnancy and lactation. FO supplementation (HFFO: 2.9% of FO in the HF diet) is given to one subgroup of HF dams during pregnancy. At weaning, male and female mHFD offspring display higher body mass, adiposity, and hepatic cellular damage, steatosis, and inflammation, accompanied by increased damaged mitochondria. FO does not protect pups from systemic metabolic alterations and partially mitigates hepatic histological damage induced by mHFD only in females. However, FO reduces mRNA expression of lipogenic genes, and mitochondrial damage, and modified mitochondrial morphology suggestive of early adaptations via mitochondrial dynamics. CONCLUSIONS: Gestational FO supplementation has limited beneficial effects on the damage caused by perinatal mHFD consumption in offspring's liver at weaning. However, FO imprinting effect on lipid metabolism and mitochondria may have beneficial long-term outcomes.

Avaliação da biocompatibilidade de uma membrana de pericárdio bovino acelular e seu potencial como carreador de osteoblastos / Evaluation of the biocompatibility of an acellular bovine pericardium membrane and its potential as an osteoblast scaffold

A biocompatibilidade de uma membrana de pericárdio bovino foi avaliada em tecido subcutâneo de camundongos 3,7, 15, 30 e 60 dias após a implantação. Os componentes celulares da resposta inflamatória, a degradação da membranae as características do colágeno foram analisadas em cortes histológicos corados pela hematoxilina-eosina, tricrômico de Masson e Picro-Sírius, respectivamente. Para verificar seu potencial como carreador celular, osteoblastos humanos(hFOB1.19, ATCC) foram semeados sobre a membrana e mantidos em DMEM/F12 por 7 dias. Os resultados in vitro mostraram que os osteoblastos proliferaram em monocamada na superfície da membrana, mas sem penetrar em seu interior. A análise dos cortes histológicos demonstrou 3 dias após a implantação apenas a formação da rede de fibrina. Aos 7 dias, o material implantado estava circundado por células inflamatórias mononucleares, com pouca penetração celular no seu interior. Após 15 dias foi observado um intenso infiltrado inflamatório em contato e dentro do material,bem como sinais de degradação interna e externa. No período de 30 dias, o material, em processo bastante avançado de absorção, estava totalmente tomado por fibroblastos e macrófagos. Aos 60 dias pós-implantação, o material não foi maisdetectado em quaisquer dos animais e a tecido subcutâneo apresentava-se normal. Os cortes corados com Picro-Sírius e observados sob luz polarizada mostraram o remodelamento tecidual. Em conclusão, a membrana de pericárdio é bioabsorvívele biocompatível, porém, in vitro, não proporciona uma adequada matriz tridimensional para osteoblastos.

The biocompatibility of a pericardium membrane was evaluated in the subcutaneous tissue of mouse killed 3, 7, 15, 30 and 60 days post implantation. The cellular components of inflammatory infiltrate, the membrane degradation, and the collagen characteristic were analyzed in histological sections stained with hematoxilyn and eosin, Tricromic of Masson and Sirius Red, respectively. The potential features as a tissue engineering scaffold was tested in vitro using human osteoblasts (h.Fob 1.19, ATCC) seeded over the membrane and maintained for 7 days in DMEM/F12. We observed in vitro the monolayer proliferation of osteoblasts, but without penetrating in the membrane. The histological sections showed after 3 days of implantation only the presence of a fibrin net. At the 7-day period, mononuclear inflammatory cells were observed around the implant, but a few one were observed inside the membrane. After 15 days the inflammatory infiltrate was more intense than in the previous period and the cells were inside and in close contact to the material showing evident signs of internal and external degradation. The implant degradation was intense after 30 days and theresidual material was fulfilled of fibroblasts and macrophages. No signs of membrane were observed after 60 days in any animals and the subcutaneous tissue presented normal aspect. Sirius Red staining at polarized light had evidenced the tissue remodeling throughout the experimental periods. In conclusion, the pericardium membrane is bioabsorbable and biocompatible, but, in vitro, do not fulfill the requirements as a tridimensional scaffold to osteoblast.